News >

Despite Progress, Somatostatin Analogs Remain Frontline Standard in NETs

Brandon Scalea
Published: Wednesday, Mar 13, 2019

Jonathan Strosberg, MD

Jonathan Strosberg, MD
Although novel therapeutic strategies have shown potential in recent clinical trials, somatostatin analogs are still the frontline standard of care for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), said Jonathan R. Strosberg, MD.

“They are basically frontline drugs, and they are [used in that setting] by virtue of their proven and very significant delay in time to progression, as well as their exceptional tolerability,” said Strosberg. “[Somatostatin analogs] are extremely low-risk drugs compared with pretty much any other drug we administer in the oncology space.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication